RefuelBio ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Regnskabstal2024–2025
| 2024 | 2025 | |
|---|---|---|
| Balance — aktiver | ||
| Likvide beholdninger | 7.249.615 | 19.374.955 |
| Omsætningsaktiver i alt | 9.161.179 | 23.133.856 |
| Anlægsaktiver i alt | — | — |
| Aktiver i alt | 9.161.179 | 23.133.856 |
| Balance — passiver | ||
| Kortfristede gældsforpligtelser | 410.037 | 2.559.803 |
| Langfristede gældsforpligtelser | — | — |
| Gældsforpligtelser i alt | 410.037 | 2.559.803 |
| Selskabskapital | 181.760 | 394.272 |
| Overført resultat | -6.197.757 | 20.179.781 |
| Årets resultat | -6.197.757 | -10.526.976 |
| Egenkapital i alt | 8.751.142 | 20.574.053 |
| Resultatopgørelse | ||
| Omsætning | 0 | — |
| Resultat af primær drift | -7.994.441 | -14.170.662 |
| Resultat før skat | -7.841.321 | -13.736.161 |
| Årets resultat | -6.197.757 | -10.526.976 |
| Personaleomkostninger | 332.986 | 718.354 |
| Af- og nedskrivninger | — | — |
| Andre nøgletal | ||
| Ansatte | — | 1 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025RefuelBio ApS’ primary activity consists of early-stage research and development of a novel medical drug candidate aimed at preventing muscle loss. The Company focuses on conditions where weight loss is accompanied by muscle loss, including obesity, type 2 diabetes, and other related medical indications. At present, the Company does not generate significant commercial revenue, as its activities are primarily related to research and development.
The income statement for 2025 shows a loss of DKK 10,527 thousand against a loss of DKK 6,198 thousand last year, and the balance sheet at 31 December 2025 shows equity of DKK 20,574 thousand. Capital increaseIn 2025, the Company conducted two capital increases, resulting in the issuance of a total of 212,512 shares with a nominal value of DKK 1 each. The total net proceeds received from these capital increases amounted to DKK 22.3 million.Financing and going concern assumptionThe financial statements have been prepared on a going concern basis. The Company incurs losses from its operations and is financed through cash capital increases. Based on the Company’s net current assets, a cash capital increase completed after the balance sheet date, and management’s plans for operations in 2026, management has concluded that the Company is able to continue its operations as a going concern for at least 12 months from the balance sheet date and through 31 December 2026.
Uddrag af ledelsesberetningen i den seneste årsrapport.